Watch for the S-4 filing and shareholder vote timeline. The $150 million minimum cash condition and sponsor forfeiture mechanism create a floor for deal viability — monitor redemption levels as a key risk factor.
Price Chart
Executive Summary
TCGX Acquisition Corp. (TCGX) announced a definitive business combination with TriGemX Bio, Inc., a clinical-stage biotech company (formerly Kallyope). The deal values TriGemX at a $361 million pre-money equity value. TCGX will domesticate from the Cayman Islands to Delaware and merge with TriGemX, with the combined entity to be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker 'TGEM'. A $160 million PIPE financing at $10.00/share backs the transaction, which is expected to close in Q1 2027.
Key Financial Metrics
Key Facts
- Business combination between SPAC TCGX and TriGemX Bio (formerly Kallyope) announced October 18, 2026.
- TriGemX valued at $361 million pre-money equity value.
- $160 million PIPE financing at $10.00/share from 16 million shares, anchored by TCG Crossover Fund III (affiliate of sponsor).
- Minimum cash condition of $150 million Available Closing Cash required for closing.
- Sponsor forfeiture of up to 539,062 founder shares if Available Closing Cash < $161 million.
- Closing expected in Q1 2027; post-closing entity to trade as 'TGEM' on Nasdaq.
- Board will consist of 7 directors: 6 designated by TriGemX (3 independent), 1 by TCGX.
- Lock-up: 6 months for sponsor/insiders, 30 days for Jefferies LLC.
Financial Impact
Deal valued at $361 million pre-money for TriGemX; $160 million PIPE at $10.00/share; TCGX trust account had ~$86.7 million as of agreement date.
Risk Factors
- Shareholder redemptions could reduce Available Closing Cash below $150 million minimum, jeopardizing closing.
- Regulatory and Nasdaq listing approvals required; any delay could push closing past June 30, 2027 termination date.
- TriGemX is a clinical-stage biotech (elismetrep candidate) with no approved products — pipeline risk post-merger.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-424760 |
| Document: 0001193125-26-424760-index-headers.html | 0001193125-26-424760 |
| Document: 0001193125-26-424760-index.html | 0001193125-26-424760 |
| Document: 0001193125-26-424760.txt | 0001193125-26-424760 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 425 | $10.01 $10.00 | ▼ −0.10% | ▼ −0.63% | $10.14 (+1.30%) |
Oct 19, 2026 7d ago | 425 | $10.01 $10.00 | ▼ −0.10% | ▼ −0.63% | $10.14 (+1.30%) |
Oct 19, 2026 7d ago | 425 | $10.02 $10.01 | ▼ −0.10% | ▼ −0.44% | $10.14 (+1.20%) |
Oct 19, 2026 7d ago | 8-K | $10.02 $10.01 | ▼ −0.10% | ▼ −0.44% | $10.14 (+1.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers